Nav: Home

DoD grant: Can strength training give female soldiers a leg up on the battlefield?

February 17, 2016

As military women prepare to head into combat posts, the Department of Defense is strengthening its efforts to level the battlefield, regardless of gender.

A new clinical trial at Wake Forest University will study the effects of strength training to prevent overuse injuries in female runners which will ultimately help the U.S. Armed Forces retain female recruits and assist with military integration efforts.

The $1.6 million study is funded by the Department of Defense to gain insight in to how more female recruits can successfully complete basic training and avoid leg and foot injuries.

Professor of health and exercise science Steve Messier is the lead investigator for the STARS (Strength Training And Running Study) trial and will begin actively recruiting participants in March.

"A major problem with runners who sustain overuse injuries is a lack of strength. Similar to the civilian running literature, female soldiers tend to incur injuries to the lower extremities at a higher rate than their male counterparts," Messier said, citing one study from the U.S. Military Academy that reports injury rates among women 2.5 times greater than in men.

The study is particularly timely as approximately 225,000 previously male-only military jobs will be open to female troops beginning April 1. Medical disability discharge rates in the military have increased 600 percent over the past 25 years, including a high proportion of recruits being discharged due to lower extremity musculoskeletal injuries suffered during military training.

Messier and his research team will recruit 150 women runners, ages 18 to 60, who typically run at least five miles per week and have not sustained an overuse injury during the past six months or participated in a formal strength training program.

They will be randomized into two groups - half will participate in a strength training program in addition to their running while the other half will serve as the control group, maintaining their usual running routine.

The strength training intervention will consist primarily of lower body exercises with some core and upper extremity exercises, three days per week for nine months. Injuries for both groups will be monitored for 18 months from the day of enrollment via bi-weekly emails.

Studying civilian runners rather than military trainees will limit the confounding effects of other activities that may contribute to overuse injury, Messier said.

"We've seen consistently in retrospective studies that injured runners are weaker than non-injured runners, even in the healthy limb," Messier said. "This trial will provide the first prospective evidence on the effect of strength training in preventing overuse injuries in female runners."

This latest study builds on previous research conducted at Wake Forest. Messier is the director of the Wake Forest Runners' Clinic that uses the skills of physical therapists, orthopedic surgeons, and biomechanists to determine the causes of overuse injuries in runners. Currently, he is the principal investigator of The Runners And Injury Longitudinal Study (TRAILS) and TRAILS: Injury Recovery, which are funded by the United States Army. These studies were done to determine the differences between runners who sustain an overuse injury and those who remain injury free (TRAILS) and to determine how long recovery from injury takes and if it is accompanied by a return to pre-injury joint mechanics, muscle strength, and psychological well-being (TRAILS: Injury Recovery).

Co-investigators include health psychologist Shannon Mihalko, of Wake's health and exercise science department; David Martin, orthopedic surgery and sports medicine, Wake Forest School of Medicine; Eddie Ip, public health sciences, WFSM; Paul DeVita, East Carolina University; Wayne Cannon, Wayne Cannon Physical Therapy and Associates; and Joseph Seay, United States Army Research Institute of Environmental Medicine (USARIEM).
-end-


Wake Forest University

Related Clinical Trial Articles:

Treatment of migraine pain in randomized clinical trial
Adults experiencing a migraine of moderate or severe severity took the drug ubrogepant or placebo and reported if after two hours they were free of pain and of their most bothersome migraine-associated symptom in this randomized clinical trial.
First entirely digital clinical trial encourages physical activity
As little as a daily ping on your phone can boost physical activity, researchers from the Stanford University School of Medicine and their collaborators report in a new study.
HIV vaccine nears clinical trial following new findings
A promising vaccine that clears an HIV-like virus from monkeys is closer to human testing after a new, weakened version of the vaccine has been shown to provide similar protection as its original version.
Sickle cell drug showing promise in clinical trial
An investigational drug for the treatment of sickle cell disease is showing early promise in clinical trials for impacting biomarkers of the disease in patients, reported UConn School of Medicine researchers.
Meditation goes digital in new clinical trial
Scientists at UC San Francisco have developed a personalized digital meditation training program that significantly improved attention and memory in healthy young adults -- a group already at the peak of brain health -- in just six weeks.
Could blockchain ensure integrity of clinical trial data?
UC San Francisco researchers have created a proof-of-concept method for ensuring the integrity of clinical trials data with blockchain.
Eating crickets can be good for your gut, according to new clinical trial
A new clinical trial shows that consuming crickets can help support the growth of beneficial gut bacteria and that eating crickets is not only safe at high doses but may also reduce inflammation in the body.
Idera Pharmaceuticals presents clinical data from the ILLUMINATE-204 trial of the combination of tilsotolimod and ipilimumab for anti-PD-1 refractory metastatic melanoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Idera Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with rare cancers and rare diseases, announced results from the ongoing ILLUMINATE-204 trial investigating tilsotolimod, Idera's intratumorally-delivered Toll-like Receptor 9 agonist, in combination with ipilimumab (Yervoy®).
Clinical trial eligibility criteria a growing obstacle
Despite a decade-long call for simplification of clinical trials, the number of criteria excluding patients from participating in clinical trials for lung cancer research continues to rise.
Clinical trial looks at tramadol for opioid withdrawal
A randomized clinical trial published by JAMA Psychiatry compared tramadol extended-release with clonidine and buprenorphine for the management of opioid withdrawal symptoms in patients with opioid use disorder in a residential research setting.
More Clinical Trial News and Clinical Trial Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Uncharted
There's so much we've yet to explore–from outer space to the deep ocean to our own brains. This hour, Manoush goes on a journey through those uncharted places, led by TED Science Curator David Biello.
Now Playing: Science for the People

#555 Coronavirus
It's everywhere, and it felt disingenuous for us here at Science for the People to avoid it, so here is our episode on Coronavirus. It's ok to give this one a skip if this isn't what you want to listen to right now. Check out the links below for other great podcasts mentioned in the intro. Host Rachelle Saunders gets us up to date on what the Coronavirus is, how it spreads, and what we know and don't know with Dr Jason Kindrachuk, Assistant Professor in the Department of Medical Microbiology and infectious diseases at the University of Manitoba. And...
Now Playing: Radiolab

Dispatch 1: Numbers
In a recent Radiolab group huddle, with coronavirus unraveling around us, the team found themselves grappling with all the numbers connected to COVID-19. Our new found 6 foot bubbles of personal space. Three percent mortality rate (or 1, or 2, or 4). 7,000 cases (now, much much more). So in the wake of that meeting, we reflect on the onslaught of numbers - what they reveal, and what they hide.  Support Radiolab today at Radiolab.org/donate.